Black Diamond Therapeutics spins out Launchpad Therapeutics with $30M Series A from Versant and NEA

Black Diamond Therapeutics, Inc.

Spinout of Launchpad, an antibody-focused precision oncology company; $30M Series A led by Versant Ventures and NEA.
Black Diamond contributed undisclosed early-stage antibody programs and licensed its MAP Drug Discovery Engine to Launchpad.
Black Diamond received 9.0 million shares of Launchpad common stock (minority stake) for the contributed assets and license.
Black Diamond will continue focus on BDTX-1535, BDTX-4933, and small molecule pipeline while retaining upside via equity stake.
Launchpad will use the MAP Engine for large molecule discovery and development of novel antibody therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.